Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Hepatitis

  Free Subscription


05.04.2021

1 Am J Med
2 Gastroenterology
2 Gut
2 Hepatology
3 J Clin Gastroenterol
1 J Med Virol
2 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Med

  1. WONG RJ, Gish RG, Cheung R, Chitnis AS, et al
    Low Prevalence of Vaccination or Documented Immunity to Hepatitis A and Hepatitis B Viruses Among Individuals with Chronic Liver Disease.
    Am J Med. 2021 Mar 25. pii: S0002-9343(21)00159.
    PubMed         Abstract available


    Gastroenterology

  2. WEN X, Liu S, Lu F
    The Influence of Different Types of Serum Cholesterol on the Prognosis of Hepatitis B Virus-Related Hepatocellular Patients Needs More Attention.
    Gastroenterology. 2020;159:1190-1191.
    PubMed        

  3. EL-SERAG HB, Kanwal F, Feng Z, Marrero JA, et al
    Risk Factors for Cirrhosis in Contemporary Hepatology Practices-Findings from Texas Hepatocellular Carcinoma Consortium Cohort.
    Gastroenterology. 2020 Mar 29. pii: S0016-5085(20)30403.
    PubMed        


    Gut

  4. PAN CQ, Dai E, Duan Z, Han G, et al
    Long-term safety of infants from mothers with chronic hepatitis B treated with tenofovir disoproxil in China.
    Gut. 2021 Mar 31. pii: gutjnl-2020-322719. doi: 10.1136/gutjnl-2020-322719.
    PubMed         Abstract available

  5. TENG YX, Li MJ, Xiang BD, Zhong JH, et al
    Tenofovir may be superior to entecavir for preventing hepatocellular carcinoma and mortality in individuals chronically infected with HBV: a meta-analysis.
    Gut. 2019 Dec 16. pii: gutjnl-2019-320326. doi: 10.1136/gutjnl-2019-320326.
    PubMed        


    Hepatology

  6. NINA KIM H, Newcomb CW, Carbonari DM, Roy JA, et al
    Risk of Hepatocellular Carcinoma with Hepatitis B Viremia among HIV/Hepatitis B Virus-Coinfected Persons in North America.
    Hepatology. 2021 Mar 29. doi: 10.1002/hep.31839.
    PubMed         Abstract available

  7. GHANY MG, Lok ASF, Dienstag JL, Feinstone SM, et al
    The 2020 Nobel Prize for Medicine or Physiology for the Discovery of Hepatitis C Virus: A Triumph of Curiosity and Persistence.
    Hepatology. 2021 Mar 30. doi: 10.1002/hep.31830.
    PubMed         Abstract available


    J Clin Gastroenterol

  8. PONVILAWAN B, Rittiphairoj T, Charoenngam N, Rujirachun P, et al
    Association Between Chronic Hepatitis C Virus Infection and Esophageal Cancer: A Systematic Review and Meta-analysis.
    J Clin Gastroenterol. 2021 Mar 17. doi: 10.1097/MCG.0000000000001532.
    PubMed         Abstract available

  9. WONG RJ, Jain MK, Therapondos G, Niu B, et al
    Low Rates of Hepatitis B Virus Treatment Among Treatment-Eligible Patients in Safety-Net Health Systems.
    J Clin Gastroenterol. 2021 Mar 17. doi: 10.1097/MCG.0000000000001530.
    PubMed         Abstract available

  10. LU M, Li J, Zhou Y, Rupp LB, et al
    Trends in Cirrhosis and Mortality by Age, Sex, Race, and Antiviral Treatment Status Among US Chronic Hepatitis B Patients (2006-2016).
    J Clin Gastroenterol. 2021 Mar 17. doi: 10.1097/MCG.0000000000001522.
    PubMed         Abstract available


    J Med Virol

  11. ELHENCE A, Singh A, Anand A, Kumar R, et al
    Real-World Re-Treatment Outcomes of Direct-Acting Antiviral Therapy Failure in Patients with Chronic Hepatitis C.
    J Med Virol. 2021 Mar 30. doi: 10.1002/jmv.26971.
    PubMed         Abstract available


    PLoS One

  12. SUENAGA R, Suka M, Hirao T, Hidaka I, et al
    Cost-effectiveness of a "treat-all" strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages.
    PLoS One. 2021;16:e0248748.
    PubMed         Abstract available

  13. HERNANDEZ CJ, Trujillo D, Sicro S, Meza J, et al
    High hepatitis C virus seropositivity, viremia, and associated risk factors among trans women living in San Francisco, California.
    PLoS One. 2021;16:e0249219.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: